Quote | BioTime Inc. (NYSE:LCTX)
Last: | $0.893 |
---|---|
Change Percent: | 0.2% |
Open: | $0.9167 |
Close: | $0.893 |
High: | $0.9303 |
Low: | $0.8372 |
Volume: | 959,782 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | BioTime Inc. (NYSE:LCTX)
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Message Board Posts | BioTime Inc. (NYSE:LCTX)
Subject | By | Source | When |
---|---|---|---|
https://www.mdpi.com/2079-7737/12/5/653 | chrismiss_everyday | investorshub | 04/30/2023 11:54:42 AM |
NEWS -- RG6501 (OpRegen®) Phase 1/2a Clinical Results | Paulness | investorshub | 04/26/2023 1:22:54 PM |
April 26, 2023 8:00 AM EDT | chrismiss_everyday | investorshub | 04/26/2023 1:03:46 PM |
A systems biology approach uncovers novel disease mechanisms | chrismiss_everyday | investorshub | 04/21/2023 12:44:56 PM |
ZZZZZZZZZZZZZ | abracky | investorshub | 04/18/2023 3:37:54 PM |
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...